Living reference work entry
Celecoxib, a diaryl-substituted pyrazole drug, was developed by G. D. Searle & Company and is currently marketed by Pfizer Incorporated under the brand names Celebrex and Celebra. Celecoxib is a member of the class of agents known as non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are the most commonly used therapeutic agents for the treatment of acute pain, fever, menstrual symptoms, osteoarthritis, and rheumatoid arthritis. Because of their ability to reduce tissue inflammation, which is often associated with tumorigenesis at various sites in the body (e.g., gastrointestinal tract and lung), celecoxib and certain other NSAIDs are also considered to have a potential in cancer chemoprevention as exemplified by their ability to prevent the formation and decrease the size of polyps in familial adenomatous polyposis (FAP) patients. Orally administered celecoxib...
KeywordsFamilial Adenomatous Polyposis PI3K Pathway Human Prostate Cancer Cell Mitochondrial Membrane Permeabilization Cancer Chemoprevention
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- Schroeder CP, Kadara H, Lotan D et al (2006) Involvement of mitochondrial and akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res 66:9762–9770CrossRefPubMedGoogle Scholar
© Springer-Verlag Berlin Heidelberg 2014